Related Experiment Video
Updated: Jun 17, 2026
07:32
Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
Published on: May 23, 2025
Iron transport in Parkinson's disease
1Université Pierre & Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de Moelle Epiniére , UMR-S975, Paris, France. etienne.hirsch@upmc.fr
Parkinsonism & Related Disorders
|January 20, 2010
Summary
Dopaminergic cell death in Parkinson's disease is linked to iron accumulation. Increased expression of the divalent metal transporter 1 (DMT1) exacerbates this iron buildup and neurodegeneration.
Area of Science:
- Neuroscience
- Neurodegenerative Diseases
- Cell Biology
Background:
- Dopaminergic cell death in the substantia nigra is key to Parkinson's disease (PD), but mechanisms remain unclear.
- Iron accumulation in the substantia nigra is implicated in PD pathogenesis, potentially causing oxidative stress and neuronal death.
- Previous research excluded transferrin but noted lactoferrin receptor overexpression and increased divalent metal transporter 1 (DMT1) in PD patients.
Purpose of the Study:
- To investigate the role of DMT1 in iron accumulation and neurodegeneration in Parkinson's disease.
- To determine if DMT1 activity contributes to dopaminergic cell loss in a PD animal model.
Main Methods:
- Utilized the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
- Assessed DMT1 expression, iron levels, oxidative stress markers, and dopaminergic neuron survival in MPTP-intoxicated mice.
- Examined the effect of a DMT1 mutation impairing iron transport on neurotoxin-induced parkinsonism.
Main Results:
- DMT1 expression increased in the ventral mesencephalon of MPTP-intoxicated mice, correlating with elevated iron, oxidative stress, and dopaminergic cell loss.
- A mutation in DMT1 that hinders iron transport conferred protection against MPTP and 6-hydroxydopamine (6-OHDA) neurotoxicity.
- These findings implicate DMT1 in the iron-mediated neurodegenerative processes observed in Parkinson's disease.
Conclusions:
- Divalent metal transporter 1 (DMT1) plays a critical role in iron accumulation within the substantia nigra.
- DMT1 activity contributes significantly to iron-mediated neurodegeneration in the context of Parkinson's disease.
- Targeting DMT1 may offer a therapeutic strategy for mitigating neurodegeneration in Parkinson's disease.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...